Coronavirus Clinical Trial
Official title:
The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Coronavirus Disease 2019
NCT number | NCT04453527 |
Other study ID # | PHT/2020/37 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 28, 2020 |
Est. completion date | May 30, 2021 |
Verified date | April 2023 |
Source | Portsmouth Hospitals NHS Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
COVID-19 is a new disease and therefore it is still not clear exactly how the virus affects the body and why people are affected so differently. It causes infection in the lungs and the virus can then attack blood vessels in the lungs and other organs to spark off an inflammatory process that can make a person very ill. It also can cause damage within tiny blood vessels that makes a person's blood thicken up and stop flow in vital organs. The investigators believe complement (which is a chemical in the body which can be harmful in excess) orchestrates the inflammation and thickening of the blood that can make a person sick. The investigators now need to know which of these complement chemicals are elevated in COVID-19 and compare to healthy volunteers, and assess whether the levels are higher in people with severe lung disease. The investigators believe that if levels are increased there are special treatments that can counteract them and potentially be an effective treatment for COVID-19. In this study the investigators will measure different parts of the inflammation process to better understand what may be causing severe disease and to see if there may be benefits from a new treatment to reduce inflammation
Status | Completed |
Enrollment | 72 |
Est. completion date | May 30, 2021 |
Est. primary completion date | May 30, 2021 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 1. Adults =18 years old requiring hospital admission for COVID-19 2. COVID-19 confirmed by either*: - A positive swab (using RT-PCR) - OR based on a high level of clinical probability confirmed by the presence of typical symptoms and compatible radiological findings on imaging with no alternative cause for these findings identified by the treating physician. Exclusion Criteria: - 1. Renal replacement therapy on ITU 2. Significant trauma (including an acute fracture or significant head injury) 3. Massive transfusion of blood products 4. Confirmed bacteraemia with pathogenic organism on blood cultures or other severe bacterial infections (including abscess/empyema) which persist despite broad-spectrum antibiotics and are thought to be significantly contributing to the patient's symptoms and clinical state. Recruitment will not be delayed however pending a negative culture. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Portsmouth Hospitals NHS Trust | Portsmouth |
Lead Sponsor | Collaborator |
---|---|
Portsmouth Hospitals NHS Trust | Akari Therapuetics |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complement Activation | C5a, C5, C3, sC5b9, Bb concentration from serum | 14 days sampling time period | |
Primary | Leukotrienes Measure | LTB4 concentration from plasma | 14 days sampling time period | |
Primary | Coagulation Measure | Level of platelets, INR, APTS, D-Dimer, Fibrinogen, thrombin antithrombin complex (TAT), from citrate plasma | 14 days sampling time period | |
Primary | Hyperinflammation Measure | • CRP, Ferritin, PCT, LDH, Troponin, ALT from plasma | 14 days sampling time period | |
Primary | Cell Count | Total White Blood Cell count (including lymphocytes, monocytes and neutrophils) | 14 days sampling time period | |
Primary | Cytokines and Chemokine Measure | Level of • Pro-inflammatory - IL-1a, IL-1ß, IL-2, IL-5, IL-6, IL-7, IL-8, IL-17, GCSF, GMCSF, IFN ?, IP10, MCP-1, MIP1a, TNFa and anti inflammatory IL-4, IL-10, IL-13, IL-22, TGF-a from plasma | 14 days sampling time period | |
Primary | Endothelial dysfunction measures: | VEGF, tissue factor and PAI-1, from plasma | 14 days sampling time period |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05065827 -
Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
|
||
Recruiting |
NCT05359770 -
Association of Inspiratory Muscle Training With HD-tDCS for Assistance to Patients With Long Covid-19
|
N/A | |
Completed |
NCT04515147 -
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
|
Phase 2 | |
Not yet recruiting |
NCT06025812 -
Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)
|
N/A | |
Recruiting |
NCT05289115 -
Protocol for Assistance to Patients With Long Covid-19 Undergoing Treatment With HD-tDCS
|
N/A | |
Completed |
NCT04953078 -
A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19
|
Phase 1 | |
Completed |
NCT04779138 -
Increasing Vaccine Uptake in Underresourced Public Housing Areas
|
N/A | |
Not yet recruiting |
NCT05868239 -
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
|
N/A | |
Completed |
NCT04818164 -
Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome
|
||
Completed |
NCT04690413 -
NOWDx Test for the Detection of Antibodies to COVID-19
|
N/A | |
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Completed |
NCT04572399 -
UVA Light Device to Treat COVID-19
|
N/A | |
Recruiting |
NCT04610567 -
Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04772170 -
Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
|
||
Recruiting |
NCT04581954 -
Inflammatory Signal Inhibitors for COVID-19 (MATIS)
|
Phase 1/Phase 2 | |
Completed |
NCT04405934 -
COG-UK Project Hospital-Onset COVID-19 Infections Study
|
N/A | |
Enrolling by invitation |
NCT04484025 -
SPI-1005 Treatment in Moderate COVID-19 Patients
|
Phase 2 | |
Completed |
NCT05572840 -
Wear Your Mask, Wash Your Hands, Don't Get COVID-19
|
N/A | |
Withdrawn |
NCT04838847 -
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
|
Phase 3 | |
Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 |